Brief: Genfit Announces First Patient First Visit For Elative Phase 3 Study Evaluating Elafibranor In PBC
24/09/2020 21:43
Sept 24 (Reuters) - Genfit SA GNFT.PA :
* GENFIT ANNOUNCES FIRST PATIENT FIRST VISIT FOR ELATIVE
PHASE 3
STUDY EVALUATING ELAFIBRANOR IN PBC
Source text for Eikon: ID:nGNX130D7p
Further company coverage: GNFT.PA
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Genfit SA
See all newsFrance's Genfit H1 revenue falls due to absence of milestone payments
French and Benelux stocks-Factors to watch on September 15
Brief: Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Genfit March 31 Cash And Cash Equivalents EUR 136.1 Million